DMAC · CIK 0001401040 · operating
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for severe ischemic and inflammatory diseases. The company's pipeline is anchored by DM199, a recombinant human tissue kallikrein-1 protein currently in Phase 2/3 trials for acute ischemic stroke, with additional Phase 2 programs evaluating the candidate in preeclampsia, cardio-renal disease, and fetal growth restriction. The company also has DM300, a recombinant human ulinastatin in preclinical development for acute pancreatitis and other inflammatory conditions.
As a clinical-stage enterprise, DiaMedica generates no material revenue from product sales. The company is supported through equity financing and operates with a lean cost structure typical of early-stage biotech firms. The organization employs 27 full-time staff and is headquartered in Minneapolis, Minnesota. The company was incorporated in 2000 under Canadian federal law and transitioned to its current name in December 2016.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | — | $-0.60 | +0.0% | |
| 2023 | — | $-0.60 | -15.4% | |
| 2022 | — | $-0.52 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-17 | 0001437749-25-008018 | SEC ↗ |
| 2023-12-31 | 2024-03-19 | 0001437749-24-008522 | SEC ↗ |
| 2022-12-31 | 2023-03-28 | 0001437749-23-008189 | SEC ↗ |
| 2021-12-31 | 2022-03-14 | 0001437749-22-006163 | SEC ↗ |
| 2020-12-31 | 2021-03-10 | 0001437749-21-005541 | SEC ↗ |
| 2019-12-31 | 2020-03-23 | 0001437749-20-005906 | SEC ↗ |
| 2018-12-31 | 2019-03-19 | 0001437749-19-005272 | SEC ↗ |